Moss, 24 April 2020
Gentian Diagnostics AS announces its results for the first quarter of 2020.
The highlights include:
- Record sales revenues of MNOK 16.2 in 1Q20, up from MNOK 10.6 in 1Q19
- Sales growth of 53 % is based on strong performance of all product lines. Sales grew by 42 % YoY on a currency neutral basis
- New publications of clinical study results confirm GCAL as a promising biomarker for earlier detection and better prediction of severity of an infection
Please find the report and results presentation here:
GDAS 1Q 2020 Interim report
GDAS 1Q Interim Presentation
For further information, please contact:
Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
MeldingsID: 503693
UtstederID: GENT-ME
Marked: Merkur Market